

**I. PERSONAL INFORMATION:**

Name Ali Raza Khaki, MD, MS  
Current Position Clinical Assistant Professor  
Current Affiliation Stanford University

**II. EDUCATIONAL BACKGROUND**

**Colleges and Universities Attended**

09/2019 – 12/2020 MS, Epidemiology, University of Washington, Seattle, WA  
09/2009 – 06/2013 MD, University of California, San Diego School of Medicine  
09/2003 – 06/2007 BA, Chemistry, *magna cum laude*, Carleton College, Northfield, MN

**Residency and Fellowship Training**

07/2017 – 12/2020 Fellow in Hematology/Oncology, University of Washington, Seattle, WA  
07/2014 – 06/2016 Resident in Internal Medicine, University of California, San Francisco  
06/2013 – 06/2014 Intern in Internal Medicine, University of California, San Francisco

**Board Certification**

2020 Oncology, American Board of Internal Medicine  
2020 Hematology, American Board of Internal Medicine  
2016 Internal Medicine, American Board of Internal Medicine

**III. PROFESSIONAL APPOINTMENTS**

**Academic Appointments:**

1/2021 – 12/2024 Clinical Assistant Professor of Medicine | Oncology  
Stanford University School of Medicine, Stanford, CA

**Other Appointments:**

07/2016 – 06/2017 Hospitalist, St Luke's Hospital CPMC, San Francisco, CA

**IV. HONORS AND AWARDS**

2020 San Antonio Breast Cancer Symposium Clinical Scholar Award  
2020 Bladder Cancer Advocacy Network (BCAN) John Quale Travel Fellowship  
2019 Conquer Cancer Foundation ASCO Quality Merit Award  
2019 AACR/ASCO *Methods in Clinical Cancer Research* Workshop Attendee  
2018 Outstanding Consultant of the Month (June), University of Washington  
2016 Reza Gandjei Humanism Award, University of California, San Francisco  
2011 Gold Humanism Honor Society  
2007 Jerry Mohrig Prize in Chemistry, Carleton College, Northfield, MN  
2005 David Maitland-Robert Will Prize, Carleton College, Northfield, MN

**V. SCHOLARLY PUBLICATIONS**

**A. Peer-reviewed original research (23 total, 3 in press)**

1. **Khaki AR**, Chennupati S, Fedorenko C, et al. Utilization of systemic therapy in patients with cancer near the end-of-life in the pre- vs. post- immune checkpoint inhibitor eras. *JCO Oncol Pract* (in press, 2021).
2. Grivas P\*, **Khaki AR\***, Wise-Draper TM\*, French B\* et al. Association of clinical factors and recent anti-cancer therapy with COVID-19 severity among patients with cancer: A report from the COVID-19 and Cancer Consortium. *Ann Oncol* (in press, 2021).
3. Michailidou D, **Khaki AR**, Morelli MP, et al. Association of blood count biomarkers and clinicopathologic features with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. *Sci Rep* (in press, 2021).

4. Wagner MJ, Pollack SM, Cranmer LD, et al. Outcomes of patients with sarcoma and COVID-19 infection: a single institution cohort analysis. *Cancer Invest.* 2021 Apr;39(4):315-320.
5. **Khaki AR**, Shan Y, Nelson RE, et al. Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs cisplatin-based chemotherapy in muscle invasive bladder cancer. *Urol Oncol.* 2021 Mar 22:S1078-1439(21)00114-19. Online ahead of print.
6. Nelson AA, Cronk RJ, Lemke EA, et al. Early bone metastases are associated with worse outcomes in metastatic urothelial carcinoma. *Bladder Cancer.* 19 March 2021;7(1):33–42.
7. Esagian SM\*, **Khaki AR\***, Diamantopoulos LN, et al. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. *BJU Int.* 2021 Feb 8. Online ahead of print.
8. Diamantopoulos LN, Sekar RR, Holt SK et al. Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. *Urol Oncol.* 2021 Feb 4:S1078-1439(21)00009-0. Online ahead of print.
9. **Khaki AR**, Li A, Diamantopoulos LN, et al. A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors. *Eur Urol Oncol.* 2021 Jan 7:S2588-9311(20)30214-5. Online ahead of print.
10. Diamantopoulos LN, Holt SK, **Khaki AR**, et al. Response to neoadjuvant chemotherapy and survival in micropapillary urothelial carcinoma: data from a tertiary referral center and the Surveillance, Epidemiology, and End Results (SEER) program. *Clin Genitourin Cancer.* 2020 Oct 14:S1558-7673(20)30229-9. Online ahead of print.
11. Graham LS\*, Sokolova AO\*, **Khaki AR\***, et al. Gender differences in faculty rank and subspecialty choice among academic medical oncologists. *Cancer Invest.* 2021 Jan; 39(1):21-24.
12. **Khaki AR**, Xu Y, Cheung WY, et al. Comparison of healthcare utilization at the end-of-life among patients with cancer in Alberta, Canada versus Washington State. *JCO Oncol Pract.* 2020 Dec;16(12):e1543-e1552.
13. Kennedy LC, Wong KM, Kamat NV, et al. Untangling the multidisciplinary care web: streamlining care through an immune-related adverse events (IRAE) tumor board. *Target Oncol.* 2020 Aug;15(4):541-548.
14. Rivera DR, Peters S, Panagiotou OA et al. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study. [published online ahead of print, 2020 Jul 22]. *Cancer Discov.* 2020;CD-20-0941.
15. Miller NJ\*, **Khaki AR\***, Diamantopoulos LN, et al. Histologic Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. *J Urol.* 2020 Jul;204(1):63-70.
16. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet.* 2020 Jun 20;395(10241):1907-1918.
17. Diamantopoulos LN, **Khaki AR**, Sonpavde GP, et al. Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature. *Clin Genitourin Cancer.* 2020 Jun;18(3):e266-e276.
18. **Khaki AR**, Li A, Diamantopoulos LN, et al. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors. *Cancer.* 2020 Mar 15;126(6):1208-1216.
19. Diamantopoulos LN, **Khaki AR**, Grivas P. et al. Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes. *Bladder Cancer.* 1 Jan. 2020:71–81.
20. Di Tanna GL, **Khaki AR**, Theron G, et al. Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. *Lancet Glob Health.* 2019 Feb;7(2):e191-e199.
21. Wheeler D, Marcus P, Nguyen J, Kwong A, **Khaki AR**, Valencia V, Moriates C. Evaluation of a Resident-Led Project to Decrease Phlebotomy Rates in the Hospital: Think Twice, Stick Once. *JAMA Intern Med.* 2016 May 1;176(5):708-10.

22. Rifkin DE, **Khaki AR**, Jenny NS, et al. Association of Renin and Aldosterone With Ethnicity and Blood Pressure: The Multi-Ethnic Study of Atherosclerosis. *Am J Hypertens*. 2014 Jun;27(6):801-10.
23. **Khaki AR**, Field C, Malik S, et al. The macroscopic rate of nucleic acid translocation by hepatitis C virus helicase NS3h is dependent on both sugar and base moieties. *J Mol Biol*. 2010 Jul 16;400(3):354-78.

**B. Peer-reviewed publications (other – 1 total)**

1. **Khaki AR**. Loose regulatory standards portend a new era of imprecision oncology. *Cancer Invest*. 2020 Feb; 39(2):120-123.

**C. Non-peer-reviewed journal articles, reviews, editorials, etc. (4 total)**

1. Tripathi A, **Khaki AR**, Grivas P. Perioperative immunotherapy in muscle-invasive bladder cancer. *Eur Urol Oncol*. 2021 Feb 25:S2588-9311(21)00028-6. Online ahead of print.
2. Desai A\*, **Khaki AR\***, Kuderer NM. Use of real-world electronic health records to estimate risk, risk factors, and disparities for COVID-19 in patients with cancer. *JAMA Oncol*. 2021 Feb 1;7(2):227-229.
3. **Khaki AR**, Agarwal N, Pal SK, et al. Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest. *Cancer*. 2020 Oct 15; 126(20):4446-4450.
4. **Khaki AR**, Gadi VK, Prasad V. Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data. *J Natl Compr Canc Netw*. 2019 Dec;17(12):1456-1458.

**D. Abstracts not published in other forms (33 total)**

1. Lythgoe M, Julve M, Krell J, et al. Racial diversity and reporting in FDA registrational trials for genitourinary (GU) cancers from 2006-20. *J Clin Oncol*. 2021; 39(6\_suppl):22-22.
2. Tucker MD, Schmidt AL, Hsu CY, et al. Severe COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT). *J Clin Oncol*. 2021; 39(6\_suppl):39-39.
3. Esagian SM, **Khaki AR**, Carril-Ajuria L, et al. Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes. *J Clin Oncol*. 2021; 39(6\_suppl):406-406.
4. **Khaki AR**, Shan Y, Nelson R, et al. Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition (ICI) versus cisplatin-based chemotherapy (CBC) in muscle-invasive bladder cancer (MIBC). *J Clin Oncol*. 2021; 39(6\_suppl):419-419.
5. Koshkin VS, Sun Y, Freeman D, et al. Efficacy of enfortumab vedotin in advanced urothelial cancer: retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study. *J Clin Oncol*. 2021; 39(6\_suppl):443-443.
6. Makrakis D, Castellano D, de Kouchkovsky I, et al. Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma. *J Clin Oncol*. 2021; 39(6\_suppl):444-444.
7. Makrakis D, Diamantopoulos LN, Koshkin VS, et al. Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma. *J Clin Oncol*. 2021; 39(6\_suppl):445-445.
8. **Khaki AR**, Shah DP, Lustberg MB, et al. Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort study. SABCS. Abstract PS7-01.
9. **Khaki AR**, Xu Y, Chennupati SR, et al. Intensity of End of Life Care for Hematologic Malignancy Patients in Western Washington, United States and Alberta, Canada. *Blood*. 2020. Abstract 3421.
10. Li A, Kuderer NM, Warner JL, et al. Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry. *Blood*. 2020. Abstract 204.

11. Grivas P, Warner J, Shyr Y, et al. Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection. *Annals of Oncology*. September 2020; 31(suppl 4):S1202-1203.
12. Koshkin VS, Sun Y, Osterman CK, et al. Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer. *Annals of Oncology*. September 2020; 31(suppl 4):S594.
13. Rosovsky R, Li A, Desai A, et al. Venous thrombotic complications in cancer patients with SARS-CoV-2 infection: report from the COVID-19 and Cancer Consortium (CCC19) registry analysis. *Res Pract Thromb Haemost*. 2020; 4(Suppl 1).
14. **Khaki AR**, Diamantopoulos LN, Zimmerman M, et al. Assessing the potential cost-effectiveness of the addition of atezolizumab to first-line platinum chemotherapy in advanced urothelial cancer: Implications for value-based pricing. ASCO Annual Meeting 2020. *J Clinl Oncol*. 2020; 38(15\_suppl):5031-5031.
15. **Khaki AR**, Desai A, Schoen MW, et al. Timing of US Food and Drug Administration (FDA) cancer drug approvals relative to publication of clinical trial results. ASCO Annual Meeting 2020. *J Clinl Oncol*. 2020; 38(15\_suppl):2071-2071.
16. Graham L, **Khaki AR**, Sokolova A, et al. Gender differences in faculty rank and subspecialty choice in academic medical oncology. *J Clin Oncol*. 2020; 38(15\_suppl):11013-11013.
17. Sekar RR, Diamantopoulos LN, **Khaki AR**, et al. Sarcomatoid urothelial carcinoma: Oncologic outcomes from a tertiary center and SEER-Medicare data. *J Clinl Oncol*. 2020; 38(15\_suppl):e17033-e17033.
18. Diamantopoulos LN, Sekar RR, **Khaki AR**, et al. Perioperative blood transfusion and postoperative outcomes in patients undergoing radical cystectomy for bladder cancer. *J Clinl Oncol*. 2020; 38(15\_suppl):e17012-e17012.
19. Gyawali B, Yang PC, Rubinstein S, et al. Mismatch between mortality burden and number of FDA registrational trials in highly lethal cancers. *J Clinl Oncol*. 2020; 38(15\_suppl):2072-2072.
20. Warner JL, Sethi TK, Rivera DR, et al. Trends in FDA cancer registrational trial design over time, 1969-2020. *J Clinl Oncol*. 2020; 38(15\_suppl):2060-2060.
21. Nelson AA, Cronk R, Szabo A, et al. Emerging clinical phenotype of bone metastatic urothelial cancer (mUC): Association of early osseous metastases (EOM) and outcomes. *J Clinl Oncol*. 2020; 38(15\_suppl):e17007-e17007.
22. **Khaki AR**, Diamantopoulos LN, Miller NJ, et al. Real-world prognostic model of overall survival (OS) in patients (pts) with advanced urothelial cancer (aUC) treated with immune checkpoint inhibitors (ICI). *J Clinl Oncol*. 2020; 38(6\_suppl):447-447.
23. Diamantopoulos LN, **Khaki AR**, Gadzinski AJ, et al. Micropapillary urothelial carcinoma (mpUC): A comparative analysis of oncologic outcomes compared to conventional urothelial carcinoma (CUC). *J Clin Oncol*. 2020;38(6\_suppl):459.
24. Miller NJ, **Khaki AR**, Diamantopoulos LN, et al. Histologic subtype and response to immune checkpoint inhibitor (ICI) therapy in advanced urothelial cancer (aUC). *J Clinl Oncol*. 2020; 38(6\_suppl):495-495.
25. Diamantopoulos LN, Sekar RR, **Khaki AR**, et al. Micropapillary urothelial carcinoma (mpUC): A comparative analysis of oncologic outcomes compared to conventional urothelial carcinoma (CUC). *J Clin Oncol*. 2020;38(6\_suppl):465.
26. **Khaki AR**, Xu Y, Fedorenko CR, et al. Intensity of end-of-life (EOL) cancer care in Western Washington (WA) versus Alberta (AB), Canada (CA). *J Clin Oncol*. 2019; 37(suppl 27):89.
27. **Khaki AR**, Diamantopoulos LN, Li A, et al. Outcomes of patients (pts) with metastatic urothelial cancer (mUC) and poor performance status (PS) receiving anti-PD(L)1 agents. *J Clinl Oncol*. 2019; 37(15\_suppl):4525-4525.
28. Diamantopoulos LN, **Khaki AR**, Vakar-Lopez F, et al. Patient (pt) characteristics, treatment patterns, outcomes and prognostic factors in plasmacytoid urothelial carcinoma (PUC). *J Clin Oncol*. 2019;37(15\_suppl):e16007.

29. Nelson AA, Wright MD, **Khaki AR**, et al. Association of early bone metastases and outcomes of the bone predominant metastatic urothelial carcinoma (BP mUC) phenotype. *J Clin Oncol*. 2019;37(15\_suppl):e16016.
30. Lim H, **Khaki AR**, Johnson AK, Morduchowicz S, Zapata J, Rennke S, Ranji S, Auerbach AD. A Resident-led interprofessional collaboration to improve admission medication reconciliation. California's Macy Regional Conference on Innovations in GME. San Francisco, CA. March 20, 2016.
31. **Khaki AR**, Di Tanna G, Fielding K, Theron G, Nicol M, Dheda K, Churchyard G, Metcalfe J. The effect of automated nucleic acid amplification assays on mortality in routine care settings: meta-analysis of individual participant data. *The International Journal of Tuberculosis and Lung Disease*; Abstract nr OA-409-05.
32. **Khaki A**, Madlensky L. Screening for Lynch Syndrome using Colorectal Cancer Immunohistochemistry. Western Regional Meeting Abstracts. *Journal of Investigative Medicine* 2011;59:88-217. January 2011, Carmel, CA.
33. **Khaki A**, Dickey T, Gauger A, Agyiri A, Chihade JW. Unusual Basis of tRNAAla identity in Human mitochondria. AARS 2006. October 2006, San Diego, T-11.

## VI. GRANT FUNDING

### Completed:

1/2019 – 12/2020 Funder: NIH/NCI  
Title: Training in Cancer Biology and Transplantation  
T32 CA009515  
PI: Nancy Davidson, MD  
Role: Trainee

## VII. PATENTS

None

## VIII. EDITORIAL SERVICE

### Editorial Positions

2019 – present Associate Editor Genitourinary Medical Oncology, *theMednet*  
2020 – present Genitourinary Oncology Section editor, *HemOnc.org*  
2019 Bladder cancer page editor, *HemOnc.org*

### Ad Hoc Reviewer

2021 – present *Journal of Clinical Oncology*  
2021 – present *The Oncologist*  
2020 – present *BJU International*  
2020 – present *JCO Clinical Cancer Informatics*  
2020 – present *JAMA Network Open*  
2020 – present *Drug Discovery Today*  
2020 – present *Cancer Investigation*

## IX. SERVICE AS GRANT REVIEWER

None

## X. UNIVERSITY ADMINISTRATIVE SERVICE

None

## XI. PROFESSIONAL ORGANIZATIONS

Service

2020 – present      ASCO, Measures Steering Group  
2020 – present      ASCO, Trainee and Early Career Council

**Membership**

2020-                  Member, American Medical Informatics Association (AMIA)  
2020-                  Member, Multinational Association of Supportive Care in Cancer (MASCC)  
2017-                  Member in Training, American Society of Clinical Oncology (ASCO)  
2017-                  Associate Member, American Society of Hematology  
2009-2017          Member, American Medical Association

**XII. INVITED PRESENTATIONS**

**Grand Rounds:**

1. 2020                  “Hematology drug approvals: Increasing the counts or lowering the bar?”  
Hematology Grand Rounds, University of Washington, Seattle, WA
2. 2019                  “Renal disease in multiple myeloma and monoclonal gammopathies.”  
Hematology Grand Rounds, University of Washington, Seattle, WA
3. 2018                  “A case-based discussion of perioperative management of  
thrombocytopenia/coagulopathy in end-stage liver disease.” Hematology Grand  
Rounds, University of Washington, Seattle, WA

**National and Regional Meetings:**

1. 2018                  “Renal failure in newly diagnosed multiple myeloma”, Seattle Multiple Myeloma  
Rounds, Seattle, WA
2. 2018                  “A numbing case of NK-/T-cell lymphoma”, Seattle Lymphoma Rounds, Seattle,  
WA

**XIII. OTHER EMPLOYMENT**

06/2007-06/2009      Research Associate, Gilead Sciences, Inc., Foster City, CA